
A boost to the UAB gene therapy study to stop the progression of neurodegenerative diseases
The University signed a patent license agreement with Anew Medical, a US company developing innovative therapies for neurodegenerative diseases and cancer, that will allow them to work jointly and accelerate the development of the treatment so that it can enter the clinical phase. This gene therapy patented by UAB researchers protects mice against cognitive deficits associated with aging, improves motor function, and delays the onset of diseases such as amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease.